| Code | CSB-RA025141MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SHR-1905, targeting thymic stromal lymphopoietin (TSLP), a critical epithelial cell-derived cytokine involved in type 2 inflammatory responses. TSLP plays a pivotal role in the initiation and amplification of allergic inflammation by activating dendritic cells, which subsequently prime naïve T cells toward a Th2 phenotype. This cytokine is implicated in the pathogenesis of multiple allergic and inflammatory conditions, including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Elevated TSLP expression in epithelial tissues correlates with disease severity and contributes to airway hyperresponsiveness and tissue remodeling.
SHR-1905 (ezanolimab) is a fully humanized IgG4 monoclonal antibody that specifically binds to TSLP, preventing its interaction with the heterodimeric TSLP receptor complex. This biosimilar antibody serves as a valuable research tool for investigating TSLP-mediated inflammatory pathways, evaluating therapeutic mechanisms in preclinical disease models, and exploring biomarkers associated with type 2 immune responses.
There are currently no reviews for this product.